CYP3A4*22 is Related to Increased Plasma Levels of 4-Hydroxytamoxifen and Partially Compensates for Reduced CYP2D6 Activation of Tamoxifen

References

• Brauch H , MurdterTE , EichelbaumM , SchwabM . Pharmacogenomics of tamoxifen therapy . Clin. Chem.55 , 1770 – 1782 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Jung JA , LimHS . Association between CYP2D6 genotypes and the clinical outocomes of adjuvant tamoxifen for breast cancer: a meta-analysis . Pharmacogenomics15 ( 1 ), 49 – 60 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jordan VC , CollinsMM , RowsbyL , PrestwichG . A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity . J. Endocrinol.75 , 305 – 316 ( 1977 ).
   PubMed Web of Science ®Google Scholar
• Teunissen SF , RosingH , KoornstraRHTet al. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry . J. Chromatogr. B.877 , 2519 – 2529 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Mürdter TE , SchrothW , Bacchus-GerybadzeLet al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma . Clin. Pharmacol. Ther.89 , 708 – 717 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ahsen NV , BinderC , BrosckmollerJ , OellerichM . CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?J. Lab. Med.33 ( 5 ), 1 – 9 ( 2009 ).
   Web of Science ®Google Scholar
• Madlensky L , NatarajanL , TchuTet al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes . Clin. Pharm. Therap.89 ( 5 ), 718 – 725 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SimonSD , PearceRE , BradfordLD , KennedyMJ , LeederJS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype . Clin. Pharmacol. Ter.83 , 234 – 242 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Borges S , DestaZ , JinYet al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients . J. Clin. Pharmacol.50 , 450 – 458 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Teh LK , BertilssonL . Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance . Drug Metab. Pharmacokinet.17 ( 1 ), 55 – 67 ( 2012 ).
   Google Scholar
• Kohlrausch FB , GamaCS , LobatoMIet al. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic souther Brazilians . Pharmacogenomics10 ( 9 ), 1457 – 1466 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Friedrich DC , GenroJP , SorticaVAet al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population . PLoS ONE9 ( 10 ), e110691 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Antunes MV , LindenR , SantosTVet al. Endoxifen levels and its association With CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy . Ther. Drug Monit.34 , 422 – 431 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Irvin WJ , WalkoCM , WeckKEet al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study . J. Clin. Oncol.29 ( 24 ), 3232 – 3239 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Musshoff F , StamerUM , MadeaB . Pharmacogenetics and forensic toxicology . Forensic Sci. Int.203 , 53 – 62 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wang Z , SchuetzEG , XuY , ThummelKE . Interplay between vitamin D and the drug metabolizing enzyme CYP3A4 . J. Steroid Biochem.136 , 54 – 58 ( 2013 ).
   Google Scholar
• Wang D , GuoY , WrightonSA , CookeGE , SadeeW . Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs . Pharmacogenomics J.11 , 274 – 286 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Teft WA , GongIY , DingleBet al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy . Breast Cancer Res. Treat.139 , 95 – 105 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Heine R , BinkhorstL , de GraanAJM . Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen . Br. J. Clin. Pharmacol.78 ( 3 ), 572 – 586 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Elens L , van SchaikRH , PaninNet al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients . Pharmacogenomics12 , 1383 – 1396 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Antunes MV , RaymundoS , OliveiraVet al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots – development, validation and clinical application during breast cancer adjuvant therapy . Talanta132 , 775 – 784 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bijl MJ , van SchaikRHN , LammersLAet al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users . Breast Cancer Res. Treat.118 ( 1 ), 125 – 130 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Schroth W , GoetzM , HammaUet al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen . JAMA302 ( 13 ), 1429 – 1436 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Jager NGL , RosingH , SchellensJHM , LinnSC , BeijnenJH . Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care . Breast Cancer Res. Treat.143 , 477 – 483 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Heath DD , FlatSW , WuAH , PruittMA , RockCL . Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods . Br. J. Biomed. Sci.71 , 33 – 39 ( 2014 ).
   PubMed Web of Science ®Google Scholar